Royalty Pharma
Zenas BioPharma Secures $300M Royalty Deal for Obexelimab FDA Approvals
Zenas BioPharma; Royalty Pharma; Obexelimab; autoimmune diseases; IgG4-Related Disease; Systemic Lupus Erythematosus; FDA approval; royalty agreement; Phase 3 INDIGO trial; funding